David Basanta (@cancerevo.org)
Excellent presentation at @mathonco.bsky.social today by UNC’s Adam Palmer describing #mathonco models that can make predictions about combination therapies in #cancer
Related Articles
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
Dr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.
Health Care Advocacy During Elections with Alice Chen, MD
October 31, 2024 47 min listen Add topic to email alerts Receive an email when new articles are posted on Please provide your email address…
Automated patient selection and care coaches to increase advance care planning for cancer patients
AbstractBackground. Advance care planning/serious illness conversations can help clinicians understand patients’ values and preferences. There are limited
Fifth Circuit Upholds Surprise Medical Bill Dispute Pay Formula
The Biden administration’s method for calculating health-provider rates in resolving surprise medical billing disputes was upheld by the Fifth Circuit Wednesday.
HERC Tool Demonstrates Feasibility in Advancing Equitable Cancer Care
Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.
Dr Pabon on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma
Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.
OCE PULSE: November FDA Oncology Events, Recent Approvals and Publications
Click to share this newsletter with your colleagues! OCE PULSE offers a summary of FDA Oncology Center of Excellence (OCE) upcoming public events, educational opportunities,…
Frederick Howard, MD, on Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer
Frederick Howard, MD, discusses the role of targeted therapy and endocrine therapy in the patient with breast cancer, based in part on his presentation at…
Overview – 42nd Annual CFS: Innovative Cancer Therapy for Tomorrow™
Now in its 42nd year, CFS® brings together thousands of health care professionals for an exciting 3-day conference that promotes the delivery of evidence-based, state-of-the-art…
Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+/HER2– Breast Cancer
Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.